ArticleRMD open2017
Course of patients with juvenile spondyloarthritis during 4 years of observation, juvenile part of GESPIC.
Article in RMD open, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Pediatric Society of the African League Against Rheumatism juvenile idiopathic arthritis recommendations for enthesitis-related arthritis and juvenile psoriatic arthritis.Clinical rheumatology · 2025Guideline
- A randomized, double-blind, placebo-controlled 12-week trial of infliximab in patients with juvenile-onset spondyloarthritis.Arthritis research & therapy · 2022Trial
- Clinical Disease Manifestations Associated With Tumor Necrosis Factor Inhibitor Nonresponse in Juvenile Spondyloarthritis.The Journal of rheumatology · 2026Article
- Recent Advances in the Pharmacological Management of Pediatric Spondyloarthritis.Paediatric drugs · 2026Review
- Clinical characteristics and treatment patterns in ankylosing spondylitis patients undergoing total hip arthroplasty: a single-center retrospective cohort study with a two-decade comparative analysis (2001-2023).BMC musculoskeletal disorders · 2026Article
- Validation of Axial Juvenile Spondyloarthropathy Criteria in Turkish Juvenile Spondyloarthropathy Patients.Diagnostics (Basel, Switzerland) · 2025Article
- Diagnosis and Management of Non-Infectious Uveitis in Pediatric Patients.Paediatric drugs · 2024Review
- Sacroiliitis at diagnosis as a protective predictor against disease flare after stopping medication: outcomes of a Southeast Asian enthesitis-related arthritis (ERA) longitudinal cohort.Clinical rheumatology · 2022Article
- Article
- Advances in Juvenile Spondyloarthritis.Current rheumatology reports · 2021Review
- Similarities and Differences Between Juvenile and Adult Spondyloarthropathies.Frontiers in medicine · 2021Review
- Tapering of Biological Agents in Juvenile ERA Patients in Daily Clinical Practice.Frontiers in medicine · 2021Article
- The Development of Extra-Articular Manifestations in Children With Enthesitis-Related Arthritis: Natural Course or Different Disease Entity?Frontiers in medicine · 2021Article
- Juvenile Spondyloarthritis: What More Do We Know About HLA-B27, Enthesitis, and New Bone Formation?Frontiers in medicine · 2021Review
- Outcomes in Juvenile-Onset Spondyloarthritis.Frontiers in medicine · 2021Review
- Juvenile Spondyloarthritis: focus on uveitis.Pediatric rheumatology online journal · 2020Article
- Capturing the enthesitis related arthritis contemporary profile of Caucasian patients in the era of biologics.Rheumatology international · 2020Article
- Enthesitis-related arthritis: current perspectives.Open access rheumatology : research and reviews · 2019Review
- Identification of genes and signaling pathways associated with the pathogenesis of juvenile spondyloarthritis.Molecular medicine reports · 2018Article
- Enthesitis-related arthritis: monitoring and specific tools.Jornal de pediatriaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo describe the course and the 4-year outcome of juvenile spondyloarthritis (jSpA).
methodsPatients with a diagnosis of jSpA and an age at onset ≤16 years were included in the German Spondyloarthritis Inception cohort (GESPIC) and followed up prospectively for 4 years.
results118 patients (73% men, 66% HLA-B27 positive, mean age 13.5 years, mean symptom duration 2.2 years) were enrolled in 2 study centres: 52% of patients with jSpA were captured by the enthesitis-related arthritis subgroup of the International League of Associations for Rheumatology classification criteria. At inclusion, the majority of patients had active peripheral arthritis (75.4%), followed by inflammatory back pain (IBP) (19.5%) and enthesitis (16.1%). There was a significant improvement in clinical manifestations and in patient-reported outcomes over time. During the 4-year follow-up, 85% of the patients had at least 1 period of remission on drug ≥6 months, and 46% of the patients achieved remission ≥12 months without medication, of whom 68% kept this status and 32% worsened. At the end of 4 years of observation, 23% of the patients were in remission without medication, but 57% still suffered from active disease. Patients with peripheral arthritis had a likelihood of 29% for having peripheral arthritis after 4 years, whereas the likelihood of IBP persistence was 53% for those with IBP at enrolment.
conclusionsAlthough 1 quarter of patients with jSpA achieved remission off medication after 4 years, the likelihood of having recurrent or persistent disease into adulthood is substantial, particularly for jSpA with IBP. TRIAL REGISTRATION NUMBER: NCT 01277419.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.